Response to: Low level evidence supporting the choice of optimal multimodality treatment approach in patients with stage IIIA NSCLC- ain't no mountain high enough…. to keep me getting to you by Jeremic Branislav

Lung Cancer. 2018 Sep:123:174-175. doi: 10.1016/j.lungcan.2018.06.031. Epub 2018 Jul 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Clinical Decision-Making
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Disease Management
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / therapy*
  • Neoplasm Staging
  • Treatment Outcome